COVID-19 진단 시장 분석 : 제품 유형별, 시료 유형별, 검사 유형별, 모드별, 최종 용도별, 지역별(2025-2033년)

The global COVID-19 diagnostics market size reached USD 58.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 29.0 Billion by 2033.

COVID-19 diagnostics refer to the clinical tests conducted to detect the presence of the viral infection among individuals. COVID-19 is an infectious disease caused by the newly discovered zoonotic coronavirus. Some common symptoms include fever, fatigue, dry cough, shortness of breath, sore throat and body aches. The viral infection is usually diagnosed through reverse transcriptase-polymerase chain reaction (RT- PCR), antigen-based and antibody testing. These tests use reagents and kits to obtain the sample from nasopharyngeal (NP), oropharyngeal (OP) and nasal swabs, human saliva or blood. They are widely used in hospitals, laboratories, clinics, research institutes and diagnostic centers.

The sudden outbreak of coronavirus disease and an alarming increase in the number of COVID-19 cases across the globe are among the key factors creating a positive outlook for the market growth. The continuous rise in the number of daily cases has led to the widespread adoption of diagnostic tests for rapid and comprehensive testing to provide early treatment to the patients. In line with this, the increasing demand for mass testing and molecular diagnostics is contributing to the market growth. Additionally, various product innovations, such as the launch of novel antibody and serology test kits for home-testing, are acting as other growth-inducing factors. In comparison to the traditionally used testing kits, these variants are less time-consuming and can be integrated with software-based programs for accurate results. Other factors, including the implementation of favorable government polices to prevent the further spread of COVID-19 infection, along with significant improvements in the healthcare infrastructure, especially in the developing economies, are anticipated to drive the market growth.

Key Market Segmentation:

Breakup by Product Type:

• Reagents and Kits
• Instruments
• Others

Breakup by Sample Type:

• Nasopharyngeal Swabs
• Oropharyngeal Swabs
• Nasal Swabs
• Blood
• Others

Breakup by Test Type:

• Molecular (RT-PCR) Testing
• Antigen-based Testing
• Antibody (Serology) Testing
• Others

Breakup by Mode:

• Point-of-Care (PoC)
• Non-Point-of-Care (Non-PoC)

Breakup by End Use:

• Laboratories
• Hospitals
• Diagnostic Centers and Clinics
• Others

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Becton Dickinson and Company, bioMerieux SA, Bio-Rad Laboratories, Danaher Corporation, F. Hoffman-La Roche Ltd. (Roche Holding AG), Luminex Corporation, PerkinElmer Inc., Quest Diagnostics Incorporated, Robert Bosch GmbH, Seegene Inc., Siemens Aktiengesellschaft and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

• 1.What was the size of the global COVID-19 diagnostics market in 2024?
• 2.What has been the impact of COVID-19 on the global COVID-19 diagnostics market?
• 3.What are the key factors driving the global COVID-19 diagnostics market?
• 4.What is the breakup of the global COVID-19 diagnostics market based on the product type?
• 5.What is the breakup of the global COVID-19 diagnostics market based on the sample type?
• 6.What is the breakup of the global COVID-19 diagnostics market based on the test type?
• 7.What is the breakup of the global COVID-19 diagnostics market based on the mode?
• 8.What is the breakup of the global COVID-19 diagnostics market based on the end use?
• 9.What are the key regions in the global COVID-19 diagnostics market?
• 10.Who are the key players/companies in the global COVID-19 diagnostics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global COVID-19 Diagnostics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product Type

• 6.1 Reagents and Kits
  • 6.1.1 Market Trends and Forecast
• 6.2 Instruments
  • 6.2.1 Market Trends and Forecast
• 6.3 Others
  • 6.3.1 Market Trends and Forecast

7 Market Breakup by Sample Type

• 7.1 Nasopharyngeal Swabs
  • 7.1.1 Market Trends and Forecast
• 7.2 Oropharyngeal Swabs
  • 7.2.1 Market Trends and Forecast
• 7.3 Nasal Swabs
  • 7.3.1 Market Trends and Forecast
• 7.4 Blood
  • 7.4.1 Market Trends and Forecast
• 7.5 Others
  • 7.5.1 Market Trends and Forecast

8 Market Breakup by Test Type

• 8.1 Molecular (RT-PCR) Testing
  • 8.1.1 Market Trends and Forecast
• 8.2 Antigen-based Testing
  • 8.2.1 Market Trends and Forecast
• 8.3 Antibody (Serology) Testing
  • 8.3.1 Market Trends and Forecast
• 8.4 Others
  • 8.4.1 Market Trends and Forecast

9 Market Breakup by Mode

• 9.1 Point-of-Care (PoC)
  • 9.1.1 Market Trends and Forecast
• 9.2 Non-Point-of-Care (Non-PoC)
  • 9.2.1 Market Trends and Forecast

10 Market Breakup by End Use

• 10.1 Laboratories
  • 10.1.1 Market Trends and Forecast
• 10.2 Hospitals
  • 10.2.1 Market Trends and Forecast
• 10.3 Diagnostic Centers and Clinics
  • 10.3.1 Market Trends and Forecast
• 10.4 Others
  • 10.4.1 Market Trends and Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends and Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends and Forecast
• 11.2 Asia-Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends and Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends and Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends and Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends and Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends and Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends and Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends and Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends and Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends and Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends and Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends and Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends and Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends and Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends and Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends and Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends and Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends and Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends and Forecast
  • 11.5.2 Market Breakup by Country

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 Abbott Laboratories
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
    • 16.3.1.3 Financials
    • 16.3.1.4 SWOT Analysis
  • 16.3.2 Becton Dickinson and Company
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
    • 16.3.2.3 Financials
    • 16.3.2.4 SWOT Analysis
  • 16.3.3 bioMerieux SA
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
    • 16.3.3.3 Financials
    • 16.3.3.4 SWOT Analysis
  • 16.3.4 Bio-Rad Laboratories
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
    • 16.3.4.3 Financials
    • 16.3.4.4 SWOT Analysis
  • 16.3.5 Danaher Corporation
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
    • 16.3.5.3 Financials
    • 16.3.5.4 SWOT Analysis
  • 16.3.6 F. Hoffman-La Roche Ltd. (Roche Holding AG)
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
    • 16.3.6.3 Financials
  • 16.3.7 Luminex Corporation
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
    • 16.3.7.3 Financials
    • 16.3.7.4 SWOT Analysis
  • 16.3.8 PerkinElmer Inc.
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
    • 16.3.8.3 Financials
    • 16.3.8.4 SWOT Analysis
  • 16.3.9 Quest Diagnostics Incorporated
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
    • 16.3.9.3 Financials
    • 16.3.9.4 SWOT Analysis
  • 16.3.10 Robert Bosch GmbH
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
  • 16.3.11 Seegene Inc.
    • 16.3.11.1 Company Overview
    • 16.3.11.2 Product Portfolio
    • 16.3.11.3 Financials
  • 16.3.12 Siemens Aktiengesellschaft
    • 16.3.12.1 Company Overview
    • 16.3.12.2 Product Portfolio
    • 16.3.12.3 Financials
    • 16.3.12.4 SWOT Analysis
  • 16.3.13 Thermo Fisher Scientific Inc.
    • 16.3.13.1 Company Overview
    • 16.3.13.2 Product Portfolio
    • 16.3.13.3 Financials
    • 16.3.13.4 SWOT Analysis